Literature DB >> 27422619

Clinical guides for atypical hemolytic uremic syndrome in Japan.

Hideki Kato1, Masaomi Nangaku1, Hiroshi Hataya2, Toshihiro Sawai3, Akira Ashida4, Rika Fujimaru5, Yoshihiko Hidaka6, Shinya Kaname7, Shoichi Maruyama8, Takashi Yasuda9, Yoko Yoshida1, Shuichi Ito10, Motoshi Hattori11, Yoshitaka Miyakawa12, Yoshihiro Fujimura13, Hirokazu Okada14, Shoji Kagami15.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely initiation of appropriate treatment for aHUS. Recent clinical and molecular findings have resulted in several proposed classifications and definitions of thrombotic microangiopathy and aHUS. Based on recent advances in this field and the emerging international consensus to exclude secondary TMAs from the definition of aHUS, we have redefined aHUS and proposed diagnostic algorithms, differential diagnosis, and therapeutic strategies for aHUS.

Entities:  

Keywords:  Alternative complement pathway; Atypical hemolytic uremic syndrome; Eculizumab; Thrombotic microangiopathy

Mesh：

Year:  2016        PMID： 27422619     DOI： 10.1007/s10157-016-1276-6

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN： 1342-1751            Impact factor:   2.801


  43 in total

1.  Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.

Authors:  Fengxiao Bu; Tara Maga; Nicole C Meyer; Kai Wang; Christie P Thomas; Carla M Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

2.  Genetic studies into inherited and sporadic hemolytic uremic syndrome.

Authors:  P Warwicker; T H Goodship; R L Donne; Y Pirson; A Nicholls; R M Ward; P Turnpenny; J A Goodship
Journal:  Kidney Int       Date:  1998-04       Impact factor: 10.612

3.  [Pathophysiology of thrombotic thrombocytopenic purpura].

Authors:  Yoshihiro Fujimura; Ayami Isonishi
Journal:  Nihon Jinzo Gakkai Shi       Date:  2014

Review 4.  Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases.

Authors:  Klaus Lechner; Hanna Lena Obermeier
Journal:  Medicine (Baltimore)       Date:  2012-07       Impact factor: 1.889

5.  Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.

Authors:  Fadi Fakhouri; Lubka Roumenina; François Provot; Marion Sallée; Sophie Caillard; Lionel Couzi; Marie Essig; David Ribes; Marie-Agnès Dragon-Durey; Frank Bridoux; Eric Rondeau; Veronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 10.121

6.  Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Christoph Licht; Jens Goebel; Bradley P Dixon; Kejian Zhang; Theru A Sivakumaran; Stella M Davies; Fred G Pluthero; Lily Lu; Benjamin L Laskin
Journal:  Blood       Date:  2013-06-27       Impact factor: 22.113

7.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

8.  An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Authors:  Josep M Campistol; Manuel Arias; Gema Ariceta; Miguel Blasco; Mario Espinosa; Josep M Grinyó; Manuel Praga; Roser Torra; Ramón Vilalta; Santiago Rodríguez de Córdoba
Journal:  Nefrologia       Date:  2013-01-18       Impact factor: 2.033

9.  Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.

Authors:  Christoph Licht; Larry A Greenbaum; Petra Muus; Sunil Babu; Camille L Bedrosian; David J Cohen; Yahsou Delmas; Kenneth Douglas; Richard R Furman; Osama A Gaber; Timothy Goodship; Maria Herthelius; Maryvonne Hourmant; Christophe M Legendre; Giuseppe Remuzzi; Neil Sheerin; Antonella Trivelli; Chantal Loirat
Journal:  Kidney Int       Date:  2015-02-04       Impact factor: 10.612

Review 10.  How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome.

Authors:  Marie Scully; Tim Goodship
Journal:  Br J Haematol       Date:  2014-01-06       Impact factor: 6.998
View more
  13 in total

Review 1.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

2.  Controversies of the classification of TMA and the terminology of aHUS.

Authors:  Hideki Kato; Masaomi Nangaku; Hirokazu Okada; Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2017-12-27       Impact factor: 2.801

3.  Clinical features in a series of 258 Japanese pediatric patients with thrombotic microangiopathy.

Authors:  Akira Ashida; Hideki Matsumura; Toshihiro Sawai; Rika Fujimaru; Yuko Fujii; Akihiko Shirasu; Hyogo Nakakura; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2018-01-19       Impact factor: 2.801

4.  Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan.

Authors:  Masanori Matsumoto; Yoshihiro Fujimura; Hideo Wada; Koichi Kokame; Yoshitaka Miyakawa; Yasunori Ueda; Satoshi Higasa; Takanori Moriki; Hideo Yagi; Toshiyuki Miyata; Mitsuru Murata
Journal:  Int J Hematol       Date:  2017-05-26       Impact factor: 2.490

5.  Hemolytic uremic syndrome in a developing country: Consensus guidelines.

Authors:  Arvind Bagga; Priyanka Khandelwal; Kirtisudha Mishra; Ranjeet Thergaonkar; Anil Vasudevan; Jyoti Sharma; Saroj Kumar Patnaik; Aditi Sinha; Sidharth Sethi; Pankaj Hari; Marie-Agnes Dragon-Durey
Journal:  Pediatr Nephrol       Date:  2019-04-15       Impact factor: 3.714

6.  Gemcitabine-induced thrombotic microangiopathy with nephrotic syndrome.

Authors:  Daisuke Katagiri; Fumihiko Hinoshita
Journal:  CEN Case Rep       Date:  2018-05-15

Review 7.  Systematic review of atypical hemolytic uremic syndrome biomarkers.

Authors:  Rupesh Raina; Sidharth K Sethi; Marie-Agnès Dragon-Durey; Amrit Khooblall; Divya Sharma; Priyanka Khandelwal; Ron Shapiro; Olivia Boyer; Hui Kim Yap; Arvind Bagga; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2022-02-03       Impact factor: 3.651

8.  Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection -is plasma exchange or eculizumab use necessary?

Authors:  Ken Saida; Masao Ogura; Yuji Kano; Shingo Ishimori; Takahisa Yoshikawa; Hiroko Nagata; Mai Sato; Koichi Kamei; Kenji Ishikura
Journal:  BMC Nephrol       Date:  2018-12-17       Impact factor: 2.388

9.  Thrombotic Microangiopathy with Polymyositis/Dermatomyositis: Three Case Reports and a Literature Review.

Authors:  Saeko Yamada; Hiroyuki Yamashita; Masahiro Nakano; Hiroaki Hatano; Toshiharu Sasaki; Yuko Takahashi; Hiroshi Kaneko
Journal:  Intern Med       Date:  2018-08-01       Impact factor: 1.271

10.  A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome.

Authors:  Masafumi Ono; Naro Ohashi; Akio Namikawa; Naoko Katahashi; Sayaka Ishigaki; Naoko Tsuji; Shinsuke Isobe; Takamasa Iwakura; Yukitoshi Sakao; Takayuki Tsuji; Akihiko Kato; Yoshihide Fujigaki; Akira Shimizu; Hideo Yasuda
Journal:  Intern Med       Date:  2018-02-09       Impact factor: 1.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.